WO2008018684A1 - Milieu de culture pour culture conjointe de cellules souches humaines et de leurs cellules nourricières - Google Patents

Milieu de culture pour culture conjointe de cellules souches humaines et de leurs cellules nourricières Download PDF

Info

Publication number
WO2008018684A1
WO2008018684A1 PCT/KR2007/002864 KR2007002864W WO2008018684A1 WO 2008018684 A1 WO2008018684 A1 WO 2008018684A1 KR 2007002864 W KR2007002864 W KR 2007002864W WO 2008018684 A1 WO2008018684 A1 WO 2008018684A1
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
cells
fbs
culture media
culture
Prior art date
Application number
PCT/KR2007/002864
Other languages
English (en)
Inventor
Hyun Sook Park
Sun Ray Lee
Jung Mi Lee
Original Assignee
Modern Cell & Tissue Technologies Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modern Cell & Tissue Technologies Inc. filed Critical Modern Cell & Tissue Technologies Inc.
Publication of WO2008018684A1 publication Critical patent/WO2008018684A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

Definitions

  • the present invention relates to a culture media composition for co-culturing human stem cells and feeder cells and for culturing a primary cell line, by which both stem cells and feeder cells can be cultivated under an optimized condition.
  • mice have been first cultured in a test tube.
  • this in vitro culture has been combined with a gene targeting technique so as to first make a transformed mouse having a targeted gene. Since that, this gene targeting technique of mice plays an important role to investigate genetic functions and to build up animal models of human diseases. Further, it drives life/medical sciences to develop a lot (Smith A. G., Annu. Rev. Cell Dev. Biol., 17: 435-62, 2001).
  • human embryonic stem cells started to be cultured in vitro, 17 years later I 1988. Dr. Thomson has first established human embryonic stem cells in University of Wisconsin (Thomson J. A., Science 282(5391): 1145-7, 1998).
  • the human embryonic stem cell is more difficult to be cultured and manipulated than the mouse stem cell. Either, it is improper to be mass-cultured, even if necessary to develop therapeutic agents by performing a gene manipulation or in vitro test. Therefore, it is required to complete a culture method that can proliferate stem cells effectively and control their quality easily.
  • the culture method popularly used is based upon the procedure Dr. Thompson established. Precisely, mouse embryonic fibroblasts are treated with mitomycin or irradiated in order to inhibit the cell growth. Then, the resulting fibroblasts are inoculated in order to previously express extra-cellular substrates and cytokines for embryonic stem cells' need. After that, embryonic stem cells are inoculated onto the resulting cells for feeder cell use.
  • the compositions of culture media are broadly classified to 2 kinds according to constituents added to basic medium.
  • the basic media is comprised of DMEM and/or DMEM/F12 (1 : 2) and may contain fibroblast growth factor, glutamine and ⁇ -mercaptoethanol.
  • 20% serum replacement(lnvitrogen Inc.) and/or 20% fetal bovine serum are added with insulin, transferrin and selenium.
  • the culture media that contains serum replacement instead of serum is improper to survive fibroblasts for feeder cell use.
  • the culture media that contains fetal bovine serum tends to differentiate stem cells a lot.
  • the culture medium of fibroblasts for feeder cell use often includes 10% fetal bovine serum, which plays an important role to survive fibroblasts. Therefore, it is clarified that fibroblasts may hardly function as feeder cells in the culture medium of embryonic stem cells containing fetal bovine serum instead of serum replacement(See FIG. 9 to 11 ; Experimental Result 3).
  • the composition of culture media for culturing embryonic stem cells should be optimized for both stem cells and feeder cells.
  • compositions of culture media for embryonic stem cells are provided.
  • compositions of culture media that comprises basic media containing fetal bovine serum(FBS), serum replacement(SR) and fibroblast growth factor(bFGF) in particular ratios. Then, we have identified that the compositions may optimize the growth of both stem cells and feeder cells and little differentiate stem cells and completed the present invention successfully.
  • FBS fetal bovine serum
  • SR serum replacement
  • bFGF fibroblast growth factor
  • the object of the present invention is to overcome conventional disadvantages of the method for culturing human embryonic stem cells.
  • the object of the present invention is to develop culture media that is optimized to survive both stem cells and feeder cells when culturing human embryonic stem cells and to maintain the capacity of undifferentiation by maximizing the function of feeder cells.
  • the object of the present invention is to improve the attachment and the growth of stem cells after restored from a freezer.
  • the culture media of the present invention may be optimized to cultivate different kinds of adult stem cells and primarily cultured cells, because it stimulate the growth of fibroblasts effectively in addition to the indifferent stem cells.
  • FIG. 1 depicts the cell numbers of feeder cells (CF1 , p5) after culturing for 60 hours by using several culture media, (a) seeding at 1,000 cells per unit area(cm 2 ); (b) at 2,000 cells per unit cm 2 .
  • FIG. 2 depicts the growth/division of feeder cells measured at various compositions of culture media when seeding at 2,000 cells per unit cm 2 according to culture periods, (a) fibroblasts derived from CF1 mice and sub-cultured during 5 passages; (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 3 depicts murine fetal fibroblasts (FIG. 2) cultured for 60 hours with several culture media by using a phase contrast microscopy (4OX magnified), (a) fibroblasts derived from CF1 mice and sub-cultured during 5 passages; (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 4 depicts the comparison of 3 kinds of culture media [general medium of fibroblasts(10% FBS), culture medium of the present invention(2% FBS, 10% SR, bFGF), culture medium for embryonic stem cell use(20% SR, bFGF)] as described in FIG. 2.
  • FIG. 5 depicts the growth/division of feeder cells measured at various compositions of culture media according to culture periods by observing the cell areas on culture plates with a CellScreen machine(lnnovatis Inc.) when seeding at 2,000 cells per unit cm 2 , (a) fibroblasts derived from CF1 mice and sub-cultured during 5 passages; (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 5 depicts the growth/division of feeder cells measured at various compositions of culture media according to culture periods by observing the cell areas on culture plates with a CellScreen machine(lnnovatis Inc.) when seeding at 2,000 cells per unit cm 2 , (a) fibroblasts derived from CF1 mice and sub-cultured during 5 passages; (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 6 depicts the growth of murine fetal fibroblasts cultured at various compositions of culture media by observing a CellScreen image of FIG. 5.
  • fibroblasts derived from CF1 mice and sub-cultured during 5 passages fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 7 depicts the comparison of 3 kinds of culture media [general medium of fibroblasts(10% FBS), culture medium of the present invention(2% FBS, 10% SR, bFGF), culture medium for embryonic stem cell use(20% SR, bFGF) as described in FIG. 5.
  • fibroblasts derived from CF1 mice and sub-cultured during 5 passages (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 8 depicts the growth of murine fetal fibroblasts cultured at various compositions of culture media by observing a CellScreen image of FIG. 7.
  • FIG. 9 depicts the cell survival of murine fetal fibroblasts according to culture media when treating mitomycin for one and a half hours to stop the cell growth by using a CellScreen image(lnnovatis Inc.).
  • fibroblasts derived from CF1 mice and sub- cultured during 5 passages fibroblasts derived from C57/Black mice and sub- cultured during 6 passages.
  • FIG. 10 depicts the comparison of 3 kinds of culture media [general medium of fibroblast ⁇ 10% FBS), culture medium of the present invention(2% FBS, 10% SR, bFGF), culture medium for embryonic stem cell use(20% SR, bFGF) as described in FIG. 9.
  • fibroblasts derived from CF1 mice and sub-cultured during 5 passages (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 11 depicts the cell survival after mitomycin treatment by observing a
  • FIG. 9 CellScreen image of FIG. 9. (a) fibroblasts derived from CF1 mice and sub-cultured during 5 passages; (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 12 depicts the comparison of cross-differentiation from murine fetal fibroblasts to muscle fibroblasts according to culture media by using an immunofluorescence staining onto ⁇ -smooth muscle actin (40X magnified), (a) and (b) fibroblasts derived from CF1 mice and sub-cultured during 5 passages; (b) fibroblasts derived from C57/Black mice and sub-cultured during 6 passages.
  • FIG. 13 depicts the comparison of attachments and undifferentiations of human embryonic stem cells cultured with general media of embryonic stem cells(20% SR, bFGF) and the culture media of the present invention(2% FBS, 10% SR, bFGF) after stored in a freezer and restored, (a) HSF6 cell line; (b) Miz4 cell line.
  • FIG. 14 depicts the attachment and the undifferentiation of human embryonic stem cells cultured with the culture media of the present invention(2% FBS 1 10% SR, bFGF) after stored in a nitrogen tank and restored for at least one month.
  • FIG. 15 depicts the undifferentiate markers SSEA4, Tral-60 and Oct4 of human embryonic stem cells cultured with the culture media of the present invention(2% FBS, 10% SR, bFGF) after stored and restored repeatedly by using a fluorescence staining.
  • FIG. 16 depicts the comparison of attachments and undifferentiations of human embryonic stem cells sub-cultured with general media of embryonic stem cells(20% SR, bFGF) and the culture media of the present invention(2% FBS, 10% SR, bFGF).
  • FIG. 17 depicts the undifferentiation of human embryonic stem cells sub- cultured with conventional media of embryonic stem cells(20% SR, bFGF) and the culture media of the present invention(2% FBS, 10% SR, bFGF).
  • FIG. 18 depicts the cell surface expression of Tral-60 marker by using a flow cytometry.
  • FIG. 19 depicts the RNA levels of Nanog, Rex1 and SOX2 markers by performing a RT-PCR.
  • FIG. 20 depicts the chromosomal aberration of human embryonic stem cells cultured with the culture media of the present invention by using a karyotype analysis.
  • FIG. 21 depicts the chromosomal aberration of human embryonic stem cells that are cultured with the culture media of the present invention after stored in a freezer and restored by using a karyotype analysis.
  • FIG. 22 depicts the cell deaths of human embryonic stem cells cultured with general media and the culture media of the present invention by using a Tunel assay.
  • FIG. 23 depicts the embryonic bodies of human embryonic stem cells cultured with culture media of the present invention to identify a tridermic differentiation.
  • FIG. 24 depicts the RNA levels of endodermic marker aFP, mesodermic marker FLKI (KDR) and ectodermic marker NCAM1 by using a RT-PCR to identify the tridermic differentiation of embryoid bodies of human embryonic stem cells cultured with the culture media of the present invention.
  • FIG. 25 depicts the protein expressions of cytokeratin(tridermic hybrid marker and epithelium marker), aFP( ⁇ -fetoprotein, endodermic marker), SMA(smooth muscle actin, mesodermic marker) and Tuj1(blll-Tubulin, ectodermic marker) by using a fluorescence staining to identify the tridermic differentiation of embryoid bodies of human embryonic stem cells cultured with the culture media of the present invention.
  • FIG. 26 depicts the human embryonic stem cells treated with nicotine amide in the culture media of the present invention.
  • FIG. 27 depicts the result of RT-PCR of human embryonic stem cell lines HSF6 and Miz4 after nicotine amide treatment at 0, 10, 50 and 100 ⁇ g/ml of concentration with culture media of the present invention, in which Oct4, Rex1 and SOX2 are undifferentiation markers.
  • FIG. 28 depicts the phenotype of MSC(mesenchymal stem cells) cultured for 5 days after seeded at 8,000 cells per unit area.
  • FIG. 29 depicts the cell number of MSC cultured for 5 days.
  • the present invention provides compositions of culture media that help the growth and the self-renewal of human stem cells as remaining indifferent.
  • conventional culture media is modified to contain fetal bovine serum(FBS), serum replacement(SR) and fibroblast growth factor(bFGF) at proper ratios in basic media.
  • the present invention provides a culture medium composition for co-culturing stem cells and feeder cells, which comprises basic media containing 1 to 10% of fetal bovine serum(FBS), 1 to 20% of serum replacement(SR) and 0.1 to 4 ng/ml of fibroblast growth factor(bFGF).
  • the present invention provides a culture medium composition for culturing a primary cell line, which comprises basic media containing 1 to 10% of fetal bovine serum(FBS), 1 to 20% of serum replacement(SR) and 0.1 to 4 ng/ml of fibroblast growth factor(bFGF).
  • basic media containing 1 to 10% of fetal bovine serum(FBS), 1 to 20% of serum replacement(SR) and 0.1 to 4 ng/ml of fibroblast growth factor(bFGF).
  • the culture media compositions of the present invention are effective to culture fibroblasts primarily.
  • This compositions of culture media are also effective to cultivate MSC (mesenchymal stem cell) or SVF (stroma vascular fraction) and primarily-cultured skin fibroblasts.
  • MSC meenchymal stem cell
  • SVF stroma vascular fraction
  • the compositions of culture media for primary culture use are the same with those of stem cells, even if the glucose level is lower.
  • the basic medium can be selected from commercially available basic media, whatever it contains essential elements for animal cell culture such as amino acids, vitamins, minerals and the like.
  • this basic medium can be selected from DMEM (Dulbecco's modified eagle medium) and DMEM/F12 (DMEM + nutrient mixture).
  • the serum replacement is a product manufactured in order to replace animal serums.
  • the serum replacement is comprised of heat-treated bovine serum albumin, bovine transferrin, bovine insulin and the like.
  • the serum replacement used in the present invention can be selected from commercially available serum replacements.
  • the serum replacement can be selected from Omni Serum(Advanced Biotechnologies Inc., Columbia, Md.) and KnockoutTM Serum Replacement(lnvitrogen Inc.; See WO098/30679) described in following Examples.
  • the present invention provides a culture medium composition, which comprises basic media containing 1 to 5% of fetal bovine serum(FBS), 5 to 15% of serum replacement(SR) and 1 to 4 ng/ml of fibroblast growth factor(bFGF).
  • FBS fetal bovine serum
  • SR serum replacement
  • bFGF fibroblast growth factor
  • the stem cells and primarily-cultured cells can be derived from embryos and/or adult tissues. That is to say, the stem cells can be selected from embryonic stem cells derived from a fetus and adult stem cells derived from a mature tissue and differentiate toward various kinds of cells;
  • the stem cells can be stored in a freezer and restored before use.
  • conventional compositions of culture media are disadvantageous to attach stem cells on a culture plate and to remain indifferent after stored in a freezer and restored.
  • the culture medium composition of the present invention is optimized to attach stem cells on a culture plate and to retain the capacity of undifferentiation effectively, even if stored in a freezer and restored before use.
  • the feeder cells can be derived from animals and humans and also derived form embryos or adult tissues, whenever they can secrete various nutrients, cytokines and the like to help stem cells and primarily-cultured cells.
  • the feeder cells can be embryonic fibroblasts(MEF) described in following Examples.
  • the culture medium composition of the present invention may contain 3 to 30 ⁇ g/ml of nicotine amide additionally.
  • stem cells can remain indifferent more effectively than those without nicotine amide.
  • stem cells are rather negatively affected(See FIG. 27).
  • the present invention provides a method for optimizing the growth of stem cells and feeder cells, which comprises culturing the stem cells and feeder cells by using the culture medium composition of the present invention.
  • “optimization” means to stimulate not only stem cells but also feeder cells to proliferate effectively.
  • the present invention provides a method for optimizing the function of feeder cells along with the growth of feeder cells, which comprises culturing the feeder cells by using the culture medium composition of the present invention.
  • the present invention provides a method for culturing stem cells by using the culture medium composition of the present invention, which maintains inherent properties of stem cells and/or primarily-cultured cells.
  • "to maintains inherent properties of stem cells” means to retain the capacity of differentiation of stem cells toward tridermic cells until necessary, even if they usually remain indifferent.
  • the present invention provides a method for optimizing the cell attachment and the undifferentiation of stem cells after stored in a freezer and restored, which comprises culturing the stem cells by using the culture medium composition of the present invention.
  • “optimization” is to improve the cell attachment and the maintenance of undifferentiation after stem cells are stored in a freezer and restored.
  • the growth rate of fibroblasts is compared by measuring cell numbers and areas of cell colonies after cultured respectively with conventional media and the culture media of the present invention(See FIG. 1 to 8;
  • FIG. 12; Experimental Result 4 the survival ratios of fibroblasts are examined by measuring the areas of cell colonies after treating mitomycin as a cytostatic agent(See FIG. 9 to 11 ; Experimental Result 3).
  • mitomycin as a cytostatic agent
  • 2 kinds of fetal fibroblasts derived from mouse strains CF1 and C57/Black are selected after primary cultures, which are commonly used for feeder cells. The same result is observed from both mouse strains.
  • the initial attachment and the maintenance of undifferentiation of stem cells are measured in their ratios, after restored from a freezer with conventional media and the culture media of the present invention(See FIG. 13; Experimental Result 5).
  • the resulting stem cells are sub-cultured during more than 8 passages and observed to monitor the maintenance of undifferentiation(See FIG. 16; Experimental Result 6).
  • 3 kinds of human embryonic stem cell lines including of HSF6, Miz4 and Miz6 are used.
  • the morphological characteristics of cell colonies are observed by using an alkaline phosphatase staining(See FIG. 17).
  • Example 1 Cell culture and composition of culture media
  • Murine embryonic fibroblasts(MEF) were extracted from 13.5 day-pregnant mice (CFI, C57BL6) and cultured primarily with following culture media.
  • the basic media was comprised of DMEM/F12 media(GIBCO, USA, Cat.No. 12500-062) mixed with 3.069 g/l sodium bicarbonate (Sigma, USA, Cat.No. S5761), 2 mM L-glutamine (Sigma, Cat.No. S8540), penicillin(50 U/ml)(Sigma, Cat.No. P4687)/streptomycin (50 ⁇ g/ml)(Sigma, USA, Cat.No.S1277). Then, 10 % fetal bovine serum(FBS; Hyclone, Cat.No. SH30070.03) or Knock-Out serum replacement(SR; Invitrogen BRL,
  • Example 2 Measurement of cell numbers After stopping cell growth, the resulting cells were washed off with PBS buffer and treated with 0.25 % Trypsin(2.5 g/L)-EDTA(0.38 g/L)(lnvitrogen BRL,
  • Human embryonic stem cells were sorted by using alkaline phosphatase staining. Stained colonies of stem cells were judged to remain indifferent and counted.
  • Example 4 CellScreen analysis Murine embryonic fibroblasts were inoculated at 2,000 cells per unit cm 2 on a
  • Example 5 Mitomycin treatment In order to inhibit the cell growth of murine embryonic fibroblasts for feeder cell use, mitomycin C (Sigma, Cat.No.M-4287) was added to culture media at 10 ⁇ g/ml of concentration and reacted for one and a half hours. Then, the resulting cells were analyzed after 14, 28 and 48 hours by using a CelIScreen machine in order to identify whether mitomycin may affect cell survival and cell death of murine embryonic fibroblasts (See FIG. 9-11 ; Experimental Result 3).
  • mitomycin C Sigma, Cat.No.M-4287
  • ⁇ -smooth muscle actin(DAKO) as a monoclonal antibody was used to detect SSEA4 (Chemicon, Cat.No.90231), TRA1-60 (Chemicon, Cat.No. MAB4360) and OCT4 (Santa cruz, Cat.No.sc-5279) markers (See FIG. 17; Experimental Result 6).
  • SSEA4 Chemicon, Cat.No.90231
  • TRA1-60 Chemicon, Cat.No. MAB4360
  • OCT4 Oxera cruz, Cat.No.sc-5279
  • aFP as an endodermic marker(Zymed, Cat.No.18-0003)
  • SMA as mesodermic marker(DAKO, Cat.No.U7033)
  • Tuj1 as an ectodermic marker(Sigma, Cat.No. c- 4585) were selected for antibodies.
  • each cell was fixed with 4% formaldehyde and permeabilized with PBS-T buffer or 1 % PBS and 0.1% Tween-20 buffer in order to perform an immuno-fluorescence staining. Then, the resulting cell was treated with blocking solution (1% PBS, 0.1 bovine serum albumin) to block non- specific antibodies. The resultant was reacted with primary antibodies ( ⁇ -smooth muscle actin) at 4 0 C overnight and then, reacted with FITC-conjugated secondary antibodies (Vector Laboratories).
  • Example 7 Restoration and cultivation of embryonic stem cells
  • Embryonic stem cells frozen in a freezer were restored and then, treated with mitomycin.
  • the stem cells were inoculated on a culture plate in which murine embryonic fibroblasts were previously incubated for a day. Then, the resulting cells were sub-cultured by the same procedure described above. 2 kinds of compositions of culture media, general media for embryonic stem cells(20% SR) and the composition of culture media of the present invention were compared while freshly exchanged everyday (See FIGs. 13, 16; Experimental Result 5, 6).
  • Colonies of embryonic stem cells were cut to proper pieces after cultured confluent.
  • the resulting colons were floated on the culture medium comprising DMEM/F12 medium containing 10% Knockout Serum replacement without bFGF and 2% FBS.
  • the cell colons were cultured by using a hydrocell(Japan) so as to prepare embryoid bodies.
  • the hydrocell is specially-treated to prevent the attachment of stem cells.
  • RNAs were extracted by using Trizol® reagent (Invitrogen, Cat.No.15596-018). Then, the resulting RNAs were reacted with AMV reverse- transcriptase at 42°C for an hour to prepare cDNAs. The resulting cDNAs were amplified by performing a PCR by 30 cycles under 95°C, 45 sec; 55°C 45 sec; 72°C 45 sec. At this moment, ⁇ -Actin, Nanog, Rex1, SOX2, aFP, FLK1 and NCAM 1 primers were used.
  • Example 10 Flow cytometry 2 kinds of human embryonic stem cells cultured respectively by using general culture media and the culture composition of the present invention were suspended to mono-cells.
  • the resulting cells were poured to PBS buffer containing BSA(bovine serum albumin) and reacted with Tral-60 (Chemicon, Cat.No.MAB4360) as a primary antibody at a low temperature for more than 3 hours.
  • Tral-60 Cemicon, Cat.No.MAB4360
  • the resultant was treated for 50 minutes with FITC anti-mouseCJacksonlmmunoResearch, Cat.No.315-095-003) as a secondary antibody and fixed with para-formaldehyde.
  • the stem cells were analyzed by performing a flow cytometry(BD).
  • cell karyotypes were analyzed. Above all, 2 kinds of human embryonic stem cells were cultured confluent by using the culture composition of the present invention. One cell kind had been sub-cultured to several passages(FIG. 20) and the other kind stored in a freezer and restored repeatedly(FIG. 21). Then, the resulting cells were treated with colcemide(0.1 ⁇ g/ml; Invitrogen) and suspended to mono-cells. After fixing the cells, G-band was observed on a slide glass. This karyotyping was conducted in at least 25 cases. As a result, it is identified that the culture composition of the present invention is so safe that embryonic stem cells do not have chromosomal aberrations.
  • Embryonic stem cells were cultured confluent and fixed with para-formaldehyde. Then, the resulting cells were treated with 0.1% Triton-X100 and permeated by Tunel reagent. At this moment, the Tunel reagent and its buffer solution(Roche, Cat.No.11- 684-795-910, Germany) were mixed in 1 : 9 of ratio and treated for more than one and a half hours at 37°C under a dark condition. The resulting cells were reacted with DAPI for 5 minutes in order to perform a nucleus staining. Then, they were observed under a fluorescence microscope to monitor the expression of fluorescence.
  • Example 12 Observation of embryonic stem cells after nicotine amide treatment
  • Human embryonic stem cells were cultured with the culture composition of the present invention in which nicotine amide was added at 10, 50 and 100 ⁇ g/ml of concentration.
  • the stem cells started to be affected remarkably by nicotine amide after more than 6-passages.
  • the stem cells remained most indifferent at 10 ⁇ g/ml of nicotine amide through a RT-PCR 1 .
  • fibroblasts were cultured by using the combinations of ITS, SR and bFGF and measured in the number after 60 hours. The initial number of cells was adjusted to 1 ,000 and 2,000 per unit cm 2 to compare differences according to cell numbers.
  • the initial number of cells was considered proper to be plated at 2,000 per unit cm 2 . Therefore, the initial number of cells was adjusted to 2,000 per unit cm 2 in following experiments.
  • the cell number did not increase sufficiently when using only serum, but increased highly when adding SR or/and ITS.
  • the fibroblasts proliferate most actively when cultured with the composition of culture media(NO. 5 in Table 2) comprising serum, SR and bFGF(See FIG. 1).
  • MEF cell growth at various compositions of culture media(FIG. 1) Cell number/cm 2 at 60 hr
  • FIG. 8 depicts the growth of murine fetal fibroblasts(CFI) by using CellScreen images according to time intervals.
  • 10% FBS was conventional feeder media for murine fibroblasts
  • 2% FBS + 10% SR + bFGF optimized media of the present invention
  • 20% SR + bFGF conventional media for human embryonic stem cell use.
  • the optimized media of the present invention become better to culture murine fibroblasts.
  • Experimental Result 3 Comparison of survival ratios of fibroblasts according to compositions of culture media after mitomycin treatment The cell numbers did not decrease only with culture media NO. 7 and NO. 8 until 46 hours, but decreased with the rest of media (See FIG. 9 to 11). Especially, the cell number of fibroblasts decreased so radically in conventional culture media for embryonic stem cell use after treated with mitomycin. As a result, it is considered that feeder cells may be difficult to survive under general culture media and hardly function due to this bad condition. The same result was observed from both mouse strains of
  • feeder cells are treated with mitomycin to inhibit the cell growth when co-cultured with human embryonic stem cells.
  • the fibroblasts for feeder cell use were observed to measure their maintenance with culture media after treated mitomycin.
  • FIG. 11 depicts CF1 cell survival after treating mitomycin for one and a half hour by using a CellScreen machine. As a result, it is identified that the composition of culture media of the present invention is also outstanding to culture feeder cells.
  • fibroblasts may cross-differentiate toward muscle fibroblasts due to the presence of TGF-b or serum, long-term culture and low-density. But, fibroblasts seldom cross-differentiate under a particular condition.
  • the cell state of fibroblasts was examined by estimating the ratios of cross-differentiation. As a result, it is judged that culture media NO. 7 to 11 may reduce the cross-differentiation(See FIG. 12). The same result was observed from both mouse strains of CR1 and C57Black.
  • human embryonic stem cell lines (HSF6 cub-cultured during 50 passages and Miz4 during 32 passages) were restored from a storage respectively with conventional media for embryonic stem cell use (20% SR + 4 ng/ml bFGF) and the culture media of the present invention (2% FBS + 10% SR + 2 ng/ml bFGF).
  • the resulting cells were seeded at 20 colonies per culture plate and stained by using alkaline phosphatase to measure degree of undifferentiation.
  • the culture media of the present invention become more outstanding to attach cells and increase the number of colonies remaining indifferent by more than 2-fold even after 5 days(See FIG. 13).
  • human embryonic stem cells cultured with the culture media of the present invention (10% SR + 2% FBS) were stored in a freezer and then, restored to measure whether they attach onto feeder cells and how they maintain undifferentiation.
  • FIG. 14 depicts the attachment and the undifferentiation of human embryonic stem cells cultured with the culture media of the present invention after stored in a nitrogen tank for at least one month and restored.
  • FIG. 13a and 13b depicts the cell attachments and cell undifferentiations of human embryonic stem cells that are continuously sub- cultured with the culture media of the present invention, then stored in a freezer and restored after a month. The resulting cells were labeled in undifferentiation markers by using a fluorescence staining. As a result, it is identified that human embryonic stem cells express the undifferentiation markers normally.
  • FIG. 13a and 13b depicts the cell attachments and cell undifferentiations of human embryonic stem cells that are continuously sub- cultured with the culture media of the present invention, then stored in a freezer and restored after a month.
  • the resulting cells were labeled in undifferentiation markers by using a fluorescence staining. As a result, it is identified that human embryonic stem cells express the undifferentiation markers normally.
  • FIG. 15 depicts the undifferentiation markers SSEA4, Tral-60 and Oct4 of human embryonic stem cells cultured with culture media of the present invention(2% FBS, 10% SR, bFGF) after repeatedly restored by using a fluorescence staining(HSF6; scale bar 10 ⁇ m).
  • the result of FIG. 15 illustrates fluorescence-stained markers of human embryonic stem cells that are continuously sub- cultured with the culture media of the present invention, then were stored in a freezer for a month and restored.
  • 3 kinds of human embryonic stem cell lines (HSF6 cub-cultured during 57 and 58 passages; Miz4 during 44 passages; and Miz6 during 35 passages) were cultured with conventional media for embryonic stem cell use (20% SR + 4 ng/ml bFGF) and the culture media of the present invention(2% FBS + 10% SR + 2 ng/ml bFGF).
  • the resulting cells were seeded at 20 colonies per culture plate. As a result, it is identified the after 24 hours, the culture media of the present invention become more outstanding to attach cells. They also increased the number of colonies remaining indifferent even after 5 days remarkably(See FIG. 16).
  • FIG. 17 depicts the undifferentiation markers of human embryonic stem cells by using a fluorescence staining. At this moment, SSEA4, Tral-60 and Oct4 are used as undifferentiation markers.
  • FIG. 17b is conventional media for human embryonic stem cell use(20% SR) and
  • FIG. 17c is the culture media of the present invention(2% FBS, 10% SR).
  • Tral-60 marker may be expressed normally with the culture media of the present invention. Further by performing a RT-PCR, the undifferentiation markers were detected.
  • FIG. 19 depicts the RNA levels of Nanog, Rex1 and SOX2 markers (expression of self- renewal markers) in 10% SR + 2% FBS medium. As a result, it is identified that Tral- 60 marker is expressed normally with the culture media of the present invention.
  • FIG. 20 depicts the chromosomal aberration of human embryonic stem cells cultured with the culture media of the present invention by using a karyotype analysis.
  • FIG. 21 depicts the chromosomal aberration of human embryonic stem cells cultured with the culture media of the present invention after stored in a freezer and restored by using a karyotype analysis.
  • FIG. 22 depicts the cell deaths of human embryonic stem cells cultured with conventional media and the culture media of the present invention by using a Tunel assay(scale bar 10 ⁇ m).
  • FIG. 23 depicts the embryonic bodies of human embryonic stem cells cultured with the culture media of the present invention in order to identify the capacity of tridermic differentiation(whole mount; scale bar 500 ⁇ m).
  • RNA levels of endodermic marker aFP, mesodermic marker FLKI(KDR) and ectodermic marker NCAM 1 by performing a RT-PCR in order to identify the capacity of tridermic differentiation of embryoid bodies of human embryonic stem cells cultured with the culture media of the present invention.
  • human embryonic stem cells were made toward embryoid bodies(EB) and cultured for a week. Then, the resulting cells were labeled in tridermic markers by using a fluorescence staining. As a result, it is identified that because all tridermic markers and all hybrid markers of endoderm, mesoderm and ectoderm are detected, human embryonic stem cells cultured with the culture media of the present invention may maintain all basic characteristics.
  • cytokeratin tridermic hybrid marker and epithelium marker
  • aFP ⁇ -fetoprotein, endodermic marker
  • SMA smooth muscle actin
  • mesodermic marker mesodermic marker
  • Tuj1 blll-Tubulin, ectodermic marker
  • FIG. 26 depicts the human embryonic stem cells treated with nicotine amide in the culture media of the present invention.
  • FIG. 27 depicts the result of RT-PCR of human embryonic stem cell lines HSF6 and Miz4 when treating 0, 10, 50 and 100 ⁇ g/ml of nicotine amide in culture media of the present invention.
  • Oct4, Rex1 and SOX2 are undifferentiation markers.
  • Experimental Result 11 Culture analysis of human adult embryonic stem cells It is identified that the compositions of culture media of the present invention are effective to culture MSC (mesenchymal stem cell), SVF (stroma vascular fraction) and the like.
  • basic media should have glucose in a low level.
  • MSC cells were seeded at 8,000 cells per unit area(cm 2 ) on a culture plate and cultured for 5 days with conventional media and the culture media of the present invention respectively. Then, the resulting cells were observed in their shapes(FIG. 28), estimated in their growth rates(FIG. 29) and calculated in their numbers by using a trypan blue staining (Sigma, Cat.No.T8-154).
  • FIG. 28 depicts the phenotype of MSC(mesenchymal stem cells) cultured for 5 days after seeded at 8,000 cells per unit area.
  • FIG. 29 depicts the cell number of MSC cultured for 5 days.
  • the present invention relates to compositions of culture media for co-culturing stem cells and feeder cells and for a primary culture of cells, by which both stem cells and feeder cells can be cultivated under an optimized condition.
  • compositions of culture media are effective to cultivate fibroblasts for feeder cell use. They are also useful to culture MSC (mesenchymal stem cell) and SVF (stroma vascular fraction) and primarily-cultured skin fibroblasts.
  • MSC mesenchymal stem cell
  • SVF stroma vascular fraction
  • the culture media of the present invention is cheaper and more conveniently optimized for both stem cells and feeder cells than conventional media.
  • this culture media is highly effective to attach stem cells and undifferentiate stem cells right after restored from a freezer. Therefore, the composition of culture media of the present invention is very useful to culture stem cells as remaining indifferent and to produce stem cells in a large scale. Furthermore, this composition of culture media can be widely applied for all kinds of cells, because it is optimized for both stem cells and primarily-cultured cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

la présente invention concerne une composition pour milieu de culture permettant de cultiver conjointement des cellules souches humaines et leurs cellules nourricières, et de cultiver une lignée cellulaire primaire. Le milieu de culture de l'invention est moins coûteux et plus facile à optimiser que des milieux classiques, tant pour des cellules souches que pour des cellules nourricières. Plus particulièrement, ce milieu de culture convient pour la fixation de cellules souches et de cellules souches indifférenciées après décongélation. C'est pourquoi, cette composition de milieu de culture convient particulièrement bien pour la culture de cellules souches indifférentes et la production de cellules souches à grande échelle. De plus, la composition de l'invention peut être largement appliquées à tous les types de cellules de culture primaire du fait qu'elle est optimisée tant pour les cellules souches que pour les fibroblastes de culture primaire.
PCT/KR2007/002864 2006-08-11 2007-06-14 Milieu de culture pour culture conjointe de cellules souches humaines et de leurs cellules nourricières WO2008018684A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20060076162 2006-08-11
KR10-2006-0076162 2006-08-11

Publications (1)

Publication Number Publication Date
WO2008018684A1 true WO2008018684A1 (fr) 2008-02-14

Family

ID=39033185

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/002864 WO2008018684A1 (fr) 2006-08-11 2007-06-14 Milieu de culture pour culture conjointe de cellules souches humaines et de leurs cellules nourricières

Country Status (2)

Country Link
KR (1) KR20090085019A (fr)
WO (1) WO2008018684A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968096B2 (en) 2014-06-27 2018-05-15 Firmenich Sa Process for preparing antimicrobial microcapsules

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114540279B (zh) * 2022-03-02 2023-05-02 生物岛实验室 干细胞无血清无饲养层培养基及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066697A2 (fr) * 2000-03-09 2001-09-13 Wisconsin Alumni Research Foundation Culture de cellules souches embryonnaires de primates exempte de serum
US20050037492A1 (en) * 2000-01-11 2005-02-17 Chunhui Xu Medium for growing human embryonic stem cells
US6998266B2 (en) * 1994-10-21 2006-02-14 Institute National De La Recherche Agronomique Active retinoic acid-free culture medium for avian totipotent embryonic stem cells
US20060073587A1 (en) * 2004-10-05 2006-04-06 Steve Stice Neuronal progenitors from feeder-free human embryonic stem cell culture

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6998266B2 (en) * 1994-10-21 2006-02-14 Institute National De La Recherche Agronomique Active retinoic acid-free culture medium for avian totipotent embryonic stem cells
US20050037492A1 (en) * 2000-01-11 2005-02-17 Chunhui Xu Medium for growing human embryonic stem cells
WO2001066697A2 (fr) * 2000-03-09 2001-09-13 Wisconsin Alumni Research Foundation Culture de cellules souches embryonnaires de primates exempte de serum
US20050148070A1 (en) * 2000-03-09 2005-07-07 Thomson James A. Cultivation of primate embryonic stem cells
US20060073587A1 (en) * 2004-10-05 2006-04-06 Steve Stice Neuronal progenitors from feeder-free human embryonic stem cell culture

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968096B2 (en) 2014-06-27 2018-05-15 Firmenich Sa Process for preparing antimicrobial microcapsules

Also Published As

Publication number Publication date
KR20090085019A (ko) 2009-08-06

Similar Documents

Publication Publication Date Title
JP7357086B2 (ja) 多能性幹細胞を培養するための新規な方法および培養培地
US20220333066A1 (en) Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
JP6581655B2 (ja) 多能性幹細胞由来ケラチノサイトの生成およびケラチノサイト培養の維持
RU2664467C2 (ru) Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
Bodnar et al. Propagation and maintenance of undifferentiated human embryonic stem cells
JP2012523240A (ja) 幹細胞培養のための方法および組成物
US20150037883A1 (en) Method for derivation and long-term establishment of ground state pluripotent embryonic stem cells
US9388388B2 (en) Methods for making cells with an extra-embryonic endodermal precursor phenotype
Vandevoort et al. Blastocyst-derived trophoblast stem cells from the rhesus monkey
JP7079017B2 (ja) 多能性幹細胞から生殖系列幹細胞様細胞への分化誘導方法
Ding et al. Feeder‐free and xeno‐free culture of human pluripotent stem cells using UCBS matrix
WO2008018684A1 (fr) Milieu de culture pour culture conjointe de cellules souches humaines et de leurs cellules nourricières
Dinger et al. Androgenetic embryonic stem cells form neural progenitor cells in vivo and in vitro
KR20100135197A (ko) 미분화 다능성줄기세포의 제작, 유지 및 증식을 위한 뉴로펩타이드 ｙ를 포함하는 배지 조성물 및 이를 이용한 다능성줄기세포의 배양 방법
KR20060089774A (ko) 서로 다른 개체로부터 유래된 체세포와 난자로부터 유래된 인간 배아 줄기세포 및 그 제조방법
Liu et al. Hair follicle dermal cells support expansion of murine and human embryonic and induced pluripotent stem cells and promote haematopoiesis in mouse cultures
He et al. Fibroblast-like cells derived from the gonadal ridges and dorsal mesenteries of human embryos as feeder cells for the culture of human embryonic germ cells
KR102581040B1 (ko) 돼지 만능성 줄기세포 배양용 배지 조성물
Feng et al. Establishment of an exogenous LIF-free culture system for mouse embryonic stem cells
CA3221435A1 (fr) Milieux sans serum pour la culture en suspension de cellules souches pluripotentes de betail de mammiferes
Aflatoonian et al. Pluripotent stem cells in vitro from human primordial germ cells
Young et al. Feeder-free Culture
Rajala Development of human stem cell culture conditions for clinical cell therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07746902

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097001645

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07746902

Country of ref document: EP

Kind code of ref document: A1